PARIS ( TheStreet) -- Sanofi-Aventis ( SNY) shares fell almost 5% Friday after its cancer drug iniparib didn't meet primary endpoints of overall survival and progression-free survival for breast cancer patients.

The Phase III clinical trial evaluated in patients with metastatic triple-negative breast cancer. The study enrolled 519 women with the cancer from 109 sites in the United States. Patients were randomized to receive a standard chemotherapy regimen (gemcitabine and carboplatin) with iniparib to one without the drug.

Sanofi-Aventis, the French drugmaker, said there wasn't a significant difference between the two regimens.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.
Copyright 2011 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe